Ferrous Bisglycinate: Absorption, Benefits & How It Compares to Other Iron Forms

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Ferrous bisglycinate is absorbed as an intact chelate via amino acid transporters separate from the pH-sensitive DMT1 pathway used by standard iron salts — making it less inhibited by phytates, calcium, and polyphenols in food, and producing significantly fewer GI side effects. Studies show comparable ferritin and hemoglobin improvements to ferrous sulfate at lower elemental doses.

Read more →

Understand what your iron supplements results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

How ferrous bisglycinate is absorbed

The chelate transport pathway

Standard iron salts (such as ferrous sulfate and ferrous gluconate) are absorbed via divalent metal transporter 1 (DMT1) in the duodenum. This pathway is pH-sensitive and is inhibited by phytates, polyphenols, calcium, and other minerals competing for the same transporter. Ferrous bisglycinate is absorbed intact as a chelate — entering intestinal cells via peptide and amino acid transporters that are separate from DMT1. This alternative uptake route means the iron bypasses many of the inhibitors that reduce standard iron absorption.

Stability in the digestive tract

The glycine chelate is stable at neutral and alkaline pH, which means ferrous bisglycinate maintains its structure even in environments where iron salts would be oxidized or precipitate. This stability is thought to explain why ferrous bisglycinate can be taken with food without the significant absorption penalty seen with ferrous sulfate, and why it produces less irritation to the gastric mucosa.

Comparative bioavailability

Studies comparing ferrous bisglycinate to ferrous sulfate in iron-deficient populations generally show equivalent or superior ferritin response with bisglycinate at lower elemental iron doses. A systematic review and meta-analysis found that ferrous bisglycinate produced comparable improvements in hemoglobin and ferritin to ferrous sulfate at lower elemental iron doses, with significantly fewer gastrointestinal adverse events. In populations where absorption is compromised — such as those with low stomach acid or those taking proton pump inhibitors — the chelate transport route may offer a meaningful practical advantage.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Ferrous bisglycinate versus other iron supplement forms

  • Ferrous sulfate — ~65 mg elemental iron per 325 mg tablet; absorbed via DMT1 (pH-dependent) with moderate to poor GI tolerability. Most prescribed and effective, but carries a high side-effect rate
  • Ferrous bisglycinate — ~25–36 mg elemental iron; absorbed via chelate/amino acid transporters with good GI tolerability. Comparable ferritin response at lower dose with less constipation
  • Ferrous gluconate — ~36 mg elemental iron per 325 mg tablet; absorbed via DMT1 (pH-dependent) with moderate GI tolerability. Better tolerated than sulfate but still pH-sensitive
  • Ferric ammonium citrate — Variable elemental iron; requires reduction to Fe2+ before absorption with moderate GI tolerability. Generally less bioavailable than ferrous forms
  • Ferric pyrophosphate (Accrufer) — 30 mg elemental iron; absorbed via a unique lipid-mediated pathway with good GI tolerability. Prescription product developed for IBD/CKD populations
  • Heme iron polypeptide — Variable elemental iron; absorbed via the heme transport receptor with good GI tolerability. Derived from hemoglobin, highly bioavailable, and less commonly available

Who may benefit from ferrous bisglycinate

People who cannot tolerate ferrous sulfate

Gastrointestinal side effects — nausea, constipation, dark stools, and abdominal cramping — are the primary reason people discontinue iron supplementation. Studies suggest that 30–50% of individuals prescribed ferrous sulfate report significant side effects that compromise adherence. Ferrous bisglycinate's improved tolerability profile makes it a practical alternative for individuals who have discontinued other forms due to side effects.

People with absorption concerns

Individuals with reduced gastric acid production (including those on proton pump inhibitors or H2 blockers), those with inflammatory bowel disease, and those with celiac disease or other malabsorptive conditions may absorb standard iron salts poorly. The chelate transport route used by ferrous bisglycinate offers an alternative pathway that is less dependent on luminal conditions.

Pregnant women and those with high iron demand

Iron requirements increase substantially during pregnancy. Ferrous bisglycinate is used in prenatal supplements and has been studied in pregnant populations, where its tolerability advantage is particularly relevant given that pregnancy already increases gastrointestinal sensitivity.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What to test before and during iron supplementation

The appropriate iron dose and duration of supplementation depends on baseline iron status, which should be established through blood testing before beginning. Testing during supplementation allows assessment of response and prevents inadvertent over-repletion.

  • Ferritin — iron stores; primary endpoint of supplementation
  • Serum iron — Circulating iron; fluctuates with recent intake and supplementation
  • Transferrin saturation — iron availability; elevated levels may indicate over-repletion
  • TIBC — total iron binding capacity; normalizes as stores are replenished
  • Hemoglobin + MCV — anemia resolution; objective marker of hematological response

Superpower's Baseline Blood Panel includes ferritin, serum iron, transferrin saturation, TIBC, hemoglobin, and MCV — the complete iron status picture. Reference ranges vary by laboratory and individual; all results should be interpreted by a qualified provider.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning iron supplementation. Superpower offers blood panels that include the biomarkers discussed in this article. Links to individual tests are provided for informational context.

Frequently Asked Questions

References

  1. Fischer JAJ, Cherian AM, Bone JN, Karakochuk CD (2023). The effects of oral ferrous bisglycinate supplementation on hemoglobin and ferritin concentrations in adults and children: a systematic review and meta-analysis of randomized controlled trials. *Nutrition reviews*, *81*(8), 904-920. https://doi.org/10.1093/nutrit/nuac106
  2. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB (2017). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. *The Lancet. Haematology*, *4*(11), e524-e533. https://doi.org/10.1016/S2352-3026(17)30182-5
  3. Milman N, Jønsson L, Dyre P, Pedersen PL, Larsen LG (2014). Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. *Journal of perinatal medicine*, *42*(2), 197-206. https://doi.org/10.1515/jpm-2013-0153
  4. Bumrungpert A, Pavadhgul P, Piromsawasdi T, Mozafari MR (2022). Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. *Nutrients*, *14*(3). https://doi.org/10.3390/nu14030452
  5. Puntarulo S (2005). Iron, oxidative stress and human health. *Molecular aspects of medicine*, *26*(4-5), 299-312. https://doi.org/10.1016/j.mam.2005.07.001

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey